Glaukos/GKOS

$90.47

-1.26%
-
1D1W1MYTD1YMAX

About Glaukos

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. The Company is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Ticker

GKOS

Sector

Healthcare

Trading on

NYSE

Industry

Medical Equipment & Supplies

CEO

Thomas Burns

Employees

907

Headquarters

Aliso viejo, United States

Glaukos Metrics

BasicAdvanced
$4.53B
Market cap
-
P/E ratio
-$2.78
EPS
1.09
Beta
-
Dividend rate

What the Analysts think about Glaukos

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
2.61% upside
High $110.00
Low $65.00
$90.47
Current price
$92.83
Average price target

Glaukos Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-44.59% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$82.3M
5.51%
Net income
$-36.7M
20.72%
Profit margin
-44.59%
14.42%

Glaukos Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.88%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$0.59
-$0.55
-$0.50
-
Expected
-$0.58
-$0.55
-$0.55
-$0.58
Surprise
2.58%
-0.81%
-8.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Glaukos stock

Buy or sell Glaukos stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing